Empagliflozin/linagliptin

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Empagliflozin/linagliptin
Empagliflozin.svg
Linagliptin.png
Combination of
EmpagliflozinSGLT2 inhibitor
LinagliptinDPP-4 inhibitor
Clinical data
License data
Routes of
administration
Oral
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
KEGG
  (verify)

Empagliflozin/linagliptin is a drug combination used for the treatment of type II diabetes. It is a combination of empagliflozin and linagliptin. The combination preparation was developed and is marketed by Boehringer Ingelheim and Eli Lilly under the trade name Glyxambi. Glyxambi was approved for use by the FDA in 2015.[1][2]

References[edit]

  1. ^ Swiatek, Jeff (2 February 2015). "2-in-1 diabetes drug from Eli Lilly and partner OK'd". The Indianapolis Star. Retrieved 3 February 2015.
  2. ^ Penumudi, Amrutha (2 February 2015). "FDA approves Boehringer-Lilly drug for type-2 diabetes patients". Reuters. Retrieved 3 February 2015.

External links[edit]